Reviews Extavia


No reviews yet.

Extavia Drug Description
Extavia
(interferon beta-1b) Kit for Subcutaneous Use
DRUG DESCRIPTION
EXTAVIA® (interferon beta-1b) is a purified, sterile, lyophilized protein
product produced by recombinant DNA techniques. Interferon beta-1b is manufactured
by bacterial fermentation of a strain of Escherichia coli that bears
a genetically engineered plasmid containing the gene for human interferon betaser17.
The native gene was obtained from human fibroblasts and altered in a way that
substitutes serine for the cysteine residue found at position 17. Interferon
beta-1b has 165 amino acids and an approximate molecular weight of 18,500 daltons.
It does not include the carbohydrate side chains found in the natural material.
EXTAVIA contains the same active ingredients as other interferon beta-1b products.
For this reason, these products should not be given concomitantly.
The specific activity of EXTAVIA is approximately 32 million international units (IU)/mg Interferon beta-1b. Each vial contains 0.3 mg of
interferon beta-1b. The unit measurement is derived by comparing the antiviral activity of the product to the World Health Organization (WHO) reference standard of recombinant human interferon beta. Mannitol, USP and Albumin (Human), USP (15 mg each/vial) are added as stabilizers.
Lyophilized EXTAVIA is a sterile, white to off-white powder, for subcutaneous injection after reconstitution with the diluent supplied (Sodium Chloride, 0.54% Solution).Last reviewed on RxList: 9/16/2009




Extavia Drug Description
Extavia
(interferon beta-1b) Kit for Subcutaneous Use
DRUG DESCRIPTION
EXTAVIA® (interferon beta-1b) is a purified, sterile, lyophilized protein
product produced by recombinant DNA techniques. Interferon beta-1b is manufactured
by bacterial fermentation of a strain of Escherichia coli that bears
a genetically engineered plasmid containing the gene for human interferon betaser17.
The native gene was obtained from human fibroblasts and altered in a way that
substitutes serine for the cysteine residue found at position 17. Interferon
beta-1b has 165 amino acids and an approximate molecular weight of 18,500 daltons.
It does not include the carbohydrate side chains found in the natural material.
EXTAVIA contains the same active ingredients as other interferon beta-1b products.
For this reason, these products should not be given concomitantly.
The specific activity of EXTAVIA is approximately 32 million international units (IU)/mg Interferon beta-1b. Each vial contains 0.3 mg of
interferon beta-1b. The unit measurement is derived by comparing the antiviral activity of the product to the World Health Organization (WHO) reference standard of recombinant human interferon beta. Mannitol, USP and Albumin (Human), USP (15 mg each/vial) are added as stabilizers.
Lyophilized EXTAVIA is a sterile, white to off-white powder, for subcutaneous injection after reconstitution with the diluent supplied (Sodium Chloride, 0.54% Solution).Last reviewed on RxList: 9/16/2009




Extavia Drug Description
Extavia
(interferon beta-1b) Kit for Subcutaneous Use
DRUG DESCRIPTION
EXTAVIA® (interferon beta-1b) is a purified, sterile, lyophilized protein
product produced by recombinant DNA techniques. Interferon beta-1b is manufactured
by bacterial fermentation of a strain of Escherichia coli that bears
a genetically engineered plasmid containing the gene for human interferon betaser17.
The native gene was obtained from human fibroblasts and altered in a way that
substitutes serine for the cysteine residue found at position 17. Interferon
beta-1b has 165 amino acids and an approximate molecular weight of 18,500 daltons.
It does not include the carbohydrate side chains found in the natural material.
EXTAVIA contains the same active ingredients as other interferon beta-1b products.
For this reason, these products should not be given concomitantly.
The specific activity of EXTAVIA is approximately 32 million international units (IU)/mg Interferon beta-1b. Each vial contains 0.3 mg of
interferon beta-1b. The unit measurement is derived by comparing the antiviral activity of the product to the World Health Organization (WHO) reference standard of recombinant human interferon beta. Mannitol, USP and Albumin (Human), USP (15 mg each/vial) are added as stabilizers.
Lyophilized EXTAVIA is a sterile, white to off-white powder, for subcutaneous injection after reconstitution with the diluent supplied (Sodium Chloride, 0.54% Solution).Last reviewed on RxList: 9/16/2009




Extavia Drug Description
Extavia
(interferon beta-1b) Kit for Subcutaneous Use
DRUG DESCRIPTION
EXTAVIA® (interferon beta-1b) is a purified, sterile, lyophilized protein
product produced by recombinant DNA techniques. Interferon beta-1b is manufactured
by bacterial fermentation of a strain of Escherichia coli that bears
a genetically engineered plasmid containing the gene for human interferon betaser17.
The native gene was obtained from human fibroblasts and altered in a way that
substitutes serine for the cysteine residue found at position 17. Interferon
beta-1b has 165 amino acids and an approximate molecular weight of 18,500 daltons.
It does not include the carbohydrate side chains found in the natural material.
EXTAVIA contains the same active ingredients as other interferon beta-1b products.
For this reason, these products should not be given concomitantly.
The specific activity of EXTAVIA is approximately 32 million international units (IU)/mg Interferon beta-1b. Each vial contains 0.3 mg of
interferon beta-1b. The unit measurement is derived by comparing the antiviral activity of the product to the World Health Organization (WHO) reference standard of recombinant human interferon beta. Mannitol, USP and Albumin (Human), USP (15 mg each/vial) are added as stabilizers.
Lyophilized EXTAVIA is a sterile, white to off-white powder, for subcutaneous injection after reconstitution with the diluent supplied (Sodium Chloride, 0.54% Solution).Last reviewed on RxList: 9/16/2009




Extavia Drug Description
Extavia
(interferon beta-1b) Kit for Subcutaneous Use
DRUG DESCRIPTION
EXTAVIA® (interferon beta-1b) is a purified, sterile, lyophilized protein
product produced by recombinant DNA techniques. Interferon beta-1b is manufactured
by bacterial fermentation of a strain of Escherichia coli that bears
a genetically engineered plasmid containing the gene for human interferon betaser17.
The native gene was obtained from human fibroblasts and altered in a way that
substitutes serine for the cysteine residue found at position 17. Interferon
beta-1b has 165 amino acids and an approximate molecular weight of 18,500 daltons.
It does not include the carbohydrate side chains found in the natural material.
EXTAVIA contains the same active ingredients as other interferon beta-1b products.
For this reason, these products should not be given concomitantly.
The specific activity of EXTAVIA is approximately 32 million international units (IU)/mg Interferon beta-1b. Each vial contains 0.3 mg of
interferon beta-1b. The unit measurement is derived by comparing the antiviral activity of the product to the World Health Organization (WHO) reference standard of recombinant human interferon beta. Mannitol, USP and Albumin (Human), USP (15 mg each/vial) are added as stabilizers.
Lyophilized EXTAVIA is a sterile, white to off-white powder, for subcutaneous injection after reconstitution with the diluent supplied (Sodium Chloride, 0.54% Solution).Last reviewed on RxList: 9/16/2009





Other reviews about Extavia on wordpress

Extavia (interferon beta-1b) and FTY720 (fingolimod) Update
  by Thixia
    EXTAVIA Approved In European Union For Treatment Of Multiple Sclerosis, First In Planned Portfolio Of Therapies From Novartis   The European Commission has approved Extavia® (interferon beta-1b) for the treatment […]


multiple sclerosis - weapons of MS destruction?
  by Jeffrey Seguritan
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (brain, spinal cord and optic nerves) that attacks the insulation of nerve cells called "myelin […]


Today's Pharma News 081709
  by Steve Woodruff
Novartis gets FDA approval for MS drug Extavia. Extavia is essentially re-branded Betaseron, and marks the entry of a new (and large player) into the MS market. It's […]


Novartis’s Big Plans for Multiple Sclerosis
  by drugsinus
The FDA gave Novartis the green light today to start selling a copy of Betaseron, the multiple sclerosis drug long sold by Bayer. Why would Novartis want […]


Diplomat Specialty Pharmacy Now Provides EXTAVIA® For Relapsing Remitting Multiple Sclerosis
  by diplomatsp
Diplomat Specialty Pharmacy is now providing EXTAVIA®  for the treatment of relapsing remitting multiple sclerosis.  At no cost to the patient or health care provider- Diplomat will: Initiate and manage the entire Insurance Prior […]


It's a biologic, it's a biosimilar, it's a bioidentical
  by healthwatcher
The back story of how the 12-year period of marketing exclusivity became part of healthcare reform also speaks to how difficult it often is to get hard facts […]


the non-shot heard round the world (in multiple sclerosis)
  by Jeffrey Seguritan
[caption id="" align="aligncenter" width="213" caption="Picture from: AIDS Research Alliance"][/caption] Pharmaceutical R&D needs a shot in the arm.  Especially in the chronic, near-debilitating disease multiple sclerosis (MS) where new drugs […]


Disease Modifying Modifying Medications
  by Cre8tivedge
I believe the most important first step when you have been diagnosed with Multiple Sclerosis is the begin a therapy drug, IMMEDIATELY!  There several alternatives for you to […]


Vision Shopsters: Commercial Insight: Multiple Sclerosis - Next generation therapies signal the start of a new era
  by visionshopsters
With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first […]



Other reviews about Extavia on web:

CALL US TODAY. For questions about EXTAVIA patient services and the EXTAVIA co-pay assistance program, call 866-925-2333. If you are a healthcare professional with product-specific Introducing Extavia®


Extavia (interferon beta-1b) is used to treat the relapsing forms of multiple sclerosis. Includes Extavia side effects, interactions and indications. Extavia Information from Drugs.com


Accurate, FDA approved Extavia information for healthcare professionals and patients - brought to you by Drugs.com. Extavia Official FDA information, side effects and uses.


Basel, August 17, 2009 - The US Food and Drug Administration (FDA) has approved Extavia® (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS ... US FDA approves Extavia® - the first in a new portfolio of ...


Learn about the prescription medication Extavia (Interferon Beta-1b Kit), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling. Extavia (Interferon Beta-1b Kit) Drug Information: Uses, Side ...


The European Commission has approved Extavia® (interferon beta-1b) for the treatment of early and relapsing forms of multiple sclerosis (MS) - the first in a new portfolio of ... EXTAVIA Approved In European Union For Treatment Of Multiple ...


The prescription drug Extavia is used as a treatment for multiple sclerosis (MS). This eMedTV Web page explores how this medicine may work for MS, explains when and how to take it ... Extavia


Do you remember when you got a “new” car, but it was really the car that your great aunt had been driving for the past 16 years? Well, that is pretty much the situation with ... Extavia is NOT a new drug for MS


Basel, May 26, 2008 - The European Commission has approved Extavia® (interferon beta-1b) for the treatment of early and relapsing forms of multiple sclerosis (MS) - the first in a ... Extavia® approved in European Union for treatment of multiple ...


Learn about EXTAVIA and its role in treating multiple sclerosis (MS) If you have just started using EXTAVIA*, you have taken a step on your way to managing your MS. Learn About EXTAVIA and: Manage Your MS





Featured Reviews

Reviews Eszopiclone

Lunesta Drug Description LUNESTA® (eszopiclone) Tablets 1 mg, 2 mg, 3 mg DRUG DESCRIPTION What are the possible side effects of eszopiclone (Lunesta)? Eszopiclone may cause a severe allergic reaction. Stop taking eszopiclone...
Read More  |  Review This
Reviews BayTet

BayTet Drug Description BayTet® Tetanus Immune Globulin (Human) Solvent/Detergent Treated 250 Units DRUG DESCRIPTION Tetanus Immune Globulin (Human) BayTet® treated with solvent/detergent is a sterile solution of tetanus hyperimmune...
Read More  |  Review This
Reviews Cystagon

Cystagon Drug Description CYSTAGON® (cysteamine bitartrate capsules) 50 mg and 150 mg DRUG DESCRIPTION What are the possible side effects of cysteamine (Cystagon)? Get emergency medical help if your child has any of these signs...
Read More  |  Review This
Reviews Anafranil

Anafranil Drug Description Anafranil® (clomipramine hydrochloride) Capsules USP 25 mg, 50 mg, and 75 mg) Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking ...
Read More  |  Review This
Reviews Pronestyl

Pronestyl Drug Description PRONESTYL (procainamide hydrochloride) Capsule, Gelatin Coated PRONESTYL (procainamide hydrochloride) Tablet, Film Coated WARNING The prolonged administration of procainamide often leads to the development ...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....